A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs
HTA Co., Ltd. · NETS Ga68 Lu177
Phase 3
Recruiting
184
2025-07
Industry sponsor intelligence
HTA Co., Ltd.Clinical Pipeline.
Lead-sponsor view of HTA Co., Ltd.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 1
- Active
- 0
- Completed
- 0
- Results posted
- 0
- Avg enrollment
- 184
Pipeline overview
Programs by phase and activity.
Velocity
HTA Co., Ltd. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 10
Phase 20
Phase 31
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Octreotide → | 1 | 0 | 0 | 1 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All HTA Co., Ltd. studies.
This page groups studies where HTA Co., Ltd. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first